India's Substitution And 'Similar' Generics Poser
Executive Summary
India's Drugs Technical Advisory Board (DTAB) has rejected a proposal to allow chemists to substitute a drug formulation with a same-ingredient generic or a cut-price brand name product, but the decision has unwittingly raised some interesting questions on how the 'pharmacy of the world' should deal with interchangeable and "similar" generics.